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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of mortality worldwide. Long-
acting bronchodilators are considered first line therapies for patients with COPD but their effects on mortality are not 
well known. We performed a comprehensive systematic review and meta-analysis to evaluate the effects of long-
acting bronchodilators on total mortality in stable COPD.
Methods: Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality 
randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in 
COPD that had a follow-up of 6 months or longer and reported on total mortality. Two reviewers independently 
abstracted data from the original trials and disagreements were resolved by iteration and consensus.
Results: Twenty-seven trials that included 30,495 patients were included in the review. Relative risk (RR) for total 
mortality was calculated for each of the study and pooled together using a random-effects model. The combination of 
inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) therapy was associated with reduced total mortality 
compared with placebo (RR, 0.80; p = 0.005). Neither tiotropium (RR, 1.08; p = 0.61) nor LABA by itself (RR, 0.90; p = 0.21) 
was associated with mortality.
Conclusions: A combination of ICS and LABA reduced mortality by approximately 20%. Neither tiotropium nor LABA 
by itself modifies all-cause mortality in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) affects
more than 300 million people worldwide [1]. It is cur-
rently the 4th leading cause of mortality accounting for
nearly 3 million deaths annually and is the only major
cause of mortality that is increasing in both the developed
and developing countries [2]. By 2020, it will become the
3rd leading cause of death (accounting for 5 million deaths
per year) and the 5th leading causing of disability world-
wide [2]. Expert guidelines recommend the use of long-
acting bronchodilators as first-line therapies for patients
with persistent symptoms [3,4]. However, their effect on
mortality remains controversial. A previous meta-analy-
sis suggested that inhaled long-acting anticholinergic
bronchodilators had no effect on total mortality [5]. On
the other hand, a secondary analysis of the UPLIFT trial
suggested a mortality benefit [6]. Similarly, although the
TORCH trial suggested a modest mortality benefit with
inhaled corticosteroid/long-acting beta-2 agonist combi-
nation (ICS/LABA), meta-analyses suggested that they
may only reduce mortality when compared to placebo [7]
or ICS alone [8] but not to LABA alone [7]. However,
there were several limitations to the prior meta-analyses,
which may have led to some of the discordant findings.
First, the prior meta-analysis on tiotropium did not
include data from the recently completed UPLIFT trial.
Second, prior meta-analyses did not address the effect of
L A B A  o n  t o t a l  m o r t a l i t y ,  m a k i n g  i t  d i f f i c u l t  t o  a s s e s s
whether or not LABA can be used as a reasonable com-
parator for ICS/LABA. Third, the findings from the ICS/
LABA on mortality are dominated by data from one trial
(i.e. TORCH), raising doubts about the robustness of the
results from previous meta-analyses. Fourth, and most
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i m p o r t a n t l y ,  m a n y  o f  t h e  p r e v i o u s  t r i a l s  o f  I C S / LA B A
used a factorial design. However, none of these studies
had sufficient power to assess interactions between treat-
ments or to adjust for multiple comparisons. From a
methodological perspective, it is essential that the active
treatment drugs be compared against one (primary) ref-
erence group (and not to each other) unless adjustments
are made for multiple comparisons [9]. To address these
limitations and to determine the effects of these drugs on
total mortality in COPD, we performed a systematic
review and meta-analysis with and without TORCH for
ICS/LABA and inclusive of UPLIFT for tiotropium.
Importantly, to maintain statistical integrity, for trials
that used a factorial design, we determined survival
effects of the primary active treatment drug against the
principal comparator group identified a priori in each of
the individual studies.
Methods
Data Sources and Searches
We examined the relationship of tiotropium, a long-act-
ing anticholinergic, as well as formoterol and salmeterol,
which are long-acting beta-2 agonists, by themselves or in
combination with an inhaled corticosteroid to all-cause
mortality. Using MEDLINE, EMBASE and Cochrane Sys-
tematic Review databases, we conducted a detailed litera-
t u r e  s e a r c h  t o  i d e n t i f y  h i g h - q u a l i t y  r a n d o m i z e d
controlled trials of tiotropium, formoterol, salmeterol,
formoterol/budesonide or salmeterol/fluticasone in
patients with stable COPD in which total mortality was
reported. We supplemented the electronic search by
reviewing the bibliographies of selected articles, examin-
ing review articles on this topic and contacting experts in
the field. Studies in abstract form were included only if
the methods and results could be adequately analyzed.
Study Selection
We restricted the search to studies that were conducted
in adults (>19 years of age), had follow-up of 6 months or
greater, and were published in the English language with
a Jadad score of 3 or greater [10]. We restricted the dura-
tion to 6 months to ensure that patients had a reasonable
window of exposure to the drugs. We excluded trials in
which there were no deaths. The details of the search are
provided in Additional File 1.
Data Extraction and Quality Assessment
Data were abstracted from each trial by 2 authors (A.K,
D.D.S) independently using a standardized data abstrac-
tion form. Any discrepancies were resolved by iteration
and consensus. The primary endpoint was total mortality
(regardless of the cause). Disease specific mortality was
not determined as assigning causality to deaths in COPD
is problematic and fraught with errors [11]. The trials
were stratified according to the study drug and to the
main comparator group. For analytic purposes, the active
treatment compound (i.e. tiotropium, formoterol, salme-
terol or formoterol/budesonide or salmeterol/flutica-
sone) was compared against the main reference group. In
most cases, the main reference group was placebo; how-
ever, we also included studies in which the main compar-
ator was another active drug (e.g. tiotropium or
salmeterol). Quality of the trials was assessed using the
QUOROM guidelines as well as using the Jadad scale
[10].
Data Synthesis and Analysis
The results were analyzed by intention-to-treat whenever
possible. To maintain the statistical integrity of the origi-
nal trial, for studies that used a factorial design, we deter-
mined the mortality rate of the active treatment drugs
against one (primary) reference group (e.g. placebo) that
were identified a priori. This mitigated the possibility of
post hoc analyses. To be conservative, a DerSimonian and
Laird random-effects model was used to pool the results
of individual trials together. The results are reported as
relative risks (RR) and 95% confidence intervals (CI). Het-
erogeneity of results across individual studies was exam-
ined using a chi-square test. All analyses were conducted
using RevMan version 5.0 (the Cochrane Collaboration,
Oxford, England).
Results
The search results are shown in figure 1. The baseline
patient characteristics of the selected studies are summa-
rized in Table 1. We identified 6 trials that compared sal-
meterol/fluticasone combination against placebo (n =
2781 in active treatment vs 2487 in placebo), 4 trials that
compared formoterol/budesonide against placebo (n =
1233 vs n = 1242), 1 trial that compared salmeterol/fluti-
casone against tiotropium (n = 658 vs 665) and 6 trials
that compared salmeterol/fluticasone against salmeterol
by itself (n = 2094 vs n = 2088). One trial was excluded as
treatment with salmeterol/fluticasone or salmeterol alone
was in addition to tiotropium, which could have led to
significant drug to drug interactions [12]. The collective
results of inhaled corticosteroid/long-acting beta-2 ago-
nist combination are summarized in figure 2. In total,
there were 269 deaths in the inhaled corticosteroid (ICS)/
long acting beta-2 agonist (LABA) arm (n = 6766) and
333 deaths in the reference group (n = 6482) for a relative
risk of 0.80 (95% CI, 0.69 to 0.94; p = 0.005) in favor of the
active treatment group. The results were largely driven by
data from Calverley et al, which accounted for 74% of the
total weight [13]. The data, however, were robust to the
exclusion of Calverley et al's study. Its exclusion resulted
in a similar risk estimate in favor of ICS/LABA combina-
tion (RR, 0.73; 95% CI, 0.54 to 0.99; p = 0.04) (figure 3).Kliber et al. Respiratory Research 2010, 11:56
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The comparison between ICS/LABA and placebo
(excluding studies that did not use a placebo comparator)
was also significant (RR, 0.83; 95% CI, 0.70 to 0.98; p =
0.03; see figure 4).
We identified 5 trials that compared salmeterol against
placebo. There were 222 deaths in the salmeterol group
(n = 2795) and 254 deaths in the placebo group (n = 2805)
for a relative risk of 0.88 (95% CI, 0.75 to 1.04; p = 0.13)
(figure 5). There were 4 trials that compared formoterol
against placebo. In these studies, there were 24 deaths in
the formoterol group (n = 1235) and 19 deaths in the pla-
cebo group (n = 1242) for a relative risk of 1.23 (95% CI,
0.61 to 2.46; p = 0.57). In total, the long-acting beta-2
agonists by themselves did not significantly alter total
mortality in COPD (RR, 0.90; 95% CI, 0.77 to 1.06; p =
0.21).
Figure 1 Flow Diagram Outlining the Search Strategy.K
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Table 1: Summary Of Clinical Trials That Were Included In This Analysis
Author N Drug 1 Drug 2 Comparator Follow-up Mean Age (SD) % Men Mean FEV1 (SD) % Current 
Smokers
Jadad 
Score
Prohibited COPD Drugs
Casaburi 2002[39] 921 TI (18 ug OD) None PL 49 weeks 64 (9) 76 1.02 (0.44) NA 3 LABA/other anticholinergics
Chan 2007[40] 913 TI (18 ug OD) None PL 48 weeks 66 (9) 60 0.97 (0.38) 32 3 other anticholinergics, oral beta agonists
Niewoehner 2005[41] 1829 TI (18 ug OD) None PL 6 months 68 (10) 99 1.04 (0.4) 30 3 other anticholinergics; oral CS >20 mg/d
Tashkin 2008[35] 5993 TI (18 ug OD) None PL 9 months 65 (8) 75 1.10 (0.4) 29 4 other anticholinergics
Tonnel 2008[42] 554 TI (18 ug OD) None PL 6 months 64 (10) 86 1.36 (0.46) 75 4 other anticholinergics
Vincken 2002[14] 535 TI (18 ug OD) None IP (40 ug QID) 6 months 64 (8) 85 1.22 (0.43) NA 3 LABAs, other anticholinergics
Brusasco 2003[43] 1207 TI (18 ug OD) SALM (50 ug BID) PL 6 months 64 (9) 76 1.10 (0.39) NA 3 Insufficient details provided
Vogelmeier 2008[44] 640 TI (18 ug OD) FORM (10 ug BID) PL 24 weeks 63 (9) 78 1.52 (0.39) NA 3 Insufficient details provided
Tashkin 2008[20] 1148 BUD/FORM (320 
ug/9 ug BID)
FORM (9 ug BID) PL 6 months 63 (10) 67 1.04 (0.41) 41 4 All prohibited except salbutamol
Szafranski 2003[45] 614 BUD/FORM (320 
ug/9 ug BID)
FORM (9 ug BID) PL 12 months 64 (NA) 80 0.98 (NA) 35 3 Only study drugs allowed
Calverley 2003[46] 765 BUD/FORM (320 
ug/9 ug BID)
FORM (9 ug BID) PL 12 months 64 (NA) 76 0.99 (0.33) 34 3 ICS, all bronchodilators except terbutaline, 
leukotriene modifiers,
Rennard 2009[21] 1470 BUD/FORM (320 
ug/9 ug BID)
FORM (9 ug BID) PL 12 months 63 (9) 64 1.01 (0.43) 42 3 All drugs except salbutamol
Ferguson 2008[47] 782 SALM/FLU (50 
ug/250 ug BID)
None SALM (50 ug 
BID)
12 months 65 (9) 56 0.94 (0.36) 40 3 ICS, LABA, TI
Kardos 2007[48] 998 SALM/FLU (50 
ug/500 ug BID)
None SALM (50 ug 
BID)
44 weeks 63 (8) 76 1.13 (0.41) 42 3 regular oral CS, LABA and TI
Wedzicha 2008[15] 1323 SALM/FLU (50 
ug/500 ug BID)
None TI 18 ug OD 24 months 64 (NA) 83 1.12 (NA) 38 4 All drugs except salbutamolK
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Calverley 2003[49] 1091 SALM/FLU (50 
ug/500 ug BID)
SALM (50 ug BID) PL 12 months 64 (NA) 73 1.26 (0.48) 52 5 Oral or inhaled CS or LABAs
SCO30002 2008 [50] 387 SALM/FLU (25 
ug/250 ug BID)
FP (250 ug BID) PL 12 months 65 (9) 82 1.54 (NA) NA 3 Not specified
SCO100540 2006[51] 445 SALM/FLU (50 
ug/500 ug BID)
None PL 6 months 66 (8) 89 1.05 (0.37) NA 3 Not specified
Mahler 2002[52] 506 SALM/FLU (50 
ug/500 ug BID)
SALM (50 ug BID) PL 24 weeks 62 (NA) 64 1.27 (NA) 50 3 Bronchodilators except salbutamol, oral CS
Calverley 2007[13] 4633 SALM/FLU (50 
ug/500 ug BID)
SALM (50 ug BID) PL 36 months 65 (8) 76 1.12 (0.4) 43 4 CS, LABA
Zheng 2007[53] 445 SALM/FLU (50 
ug/500 ug BID)
NA PL 24 weeks 66 (8) 89 1.05 (NA) 22 4 ICS, LABA
Stockley 2006[54] 634 SALM (50 ug BID) NA PL 12 months 62 (9) 77 1.30 (0.5) 40 4 TI or LABA
SCO30002 2008[55] 256 SALM/FLU (50 
ug/500 ug BID)
FLU (500 ug BID) PL 52 weeks 64 (NA) 82 1.50 (NA) NA 3 Not specified
SCO100470 2006 [56] 1050 SALM/FLU (50 
ug/250 ug BID)
None SALM (50 ug 
BID)
6 months 64 (9) 78 1.67 (0.46) NA 3 Not specified
Anzueto 2009[57] 797 SALM/FLU (50 
ug/250 ug BID)
None SALM (50 ug 
BID)
12 months 65 (NA) 54 1.17 (0.51) 42 4 All prohibited except salbutamol and 
ipratropium
SCO40041 2008 [58] 186 SALM/FLU (50 
ug/250 ug BID)
None SALM (50 ug 
BID)
3 years 66 (9) 61 NA NA 3 Not specified
Wouters 2005 [59] 373 SALM/FLU (50 
ug/500 ug BID)
None SALM (50 ug 
BID)
12 months 64 (8) 74 1.41 (0.48) 37 4 All prohibited except salbutamol, 
ipratropium and xanthines
Abbreviations:
BID, twice daily; CS, corticosteroids; FEV1, forced expiratory volume in one second; FLU, fluticasone; FORM, formoterol; ICS, inhaled corticosteroids; IP, ipratropium bromide; LABA, long acting bronchodilators, N = total sample 
size; NA, not available; OD, once daily; PL, placebo; SALM, salmeterol; SD, standard deviation; TI, tiotropium
Table 1: Summary Of Clinical Trials That Were Included In This Analysis (Continued)Kliber et al. Respiratory Research 2010, 11:56
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We identified 9 clinical trials that compared tiotropium
against placebo but one study reported no deaths and
data from one of the studies overlapped substantially with
another, leaving 7 clinical trials for analysis (figure 6). In
all, there were 431 deaths in the tiotropium group and
453 deaths in the placebo group for a relative risk of 0.94
(95% CI, 0.80 to 1.11; p = 0.46). There was one study that
compared tiotropium against ipratropium (RR, 1.51; 95%
CI, 0.41 to 5.50; p = 0.53) [14] and one that compared
tiotropium against salmeterol/fluticasone combination
(RR, 1.79; 95% CI, 1.06 to 3.02; p = 0.03) [15]. In sum,
tiotropium was not associated with total mortality (RR,
1.08; 95% CI, 0.79 to 1.48; p = 0.61). As a sensitivity analy-
sis, we excluded studies that compared tiotropium
against a comparator other than placebo or ipratropium
bromide and repeated the analysis. This made no mate-
rial impact on the results (figure 7). Tiotropium was not
associated with total mortality (RR, 0.94; 95% CI, 0.83 to
1.06; p = 0.33).
Discussion
The most important findings from the present meta-
analysis were that 1) inhaled corticosteroids (ICS) in
combination with a long-acting bronchodilator (LABA)
were associated with a ~20% reduction in total mortality;
whereas LABAs or long-acting anticholinergics by them-
Figure 2 The Effects of Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Combination on Total Mortality. Abbreviations: BUD/F, budes-
onide/formoterol combination; CI, confidence interval; ICS/LABA, inhaled corticosteroids/long-acting beta-2 agonist combination; M-H, Mantel-Han-
zel; SALM, salmeterol; SFC, salmeterol/fluticasone combination
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selves did not alter mortality; and 2) these data were
robust to the inclusion or exclusion of the TORCH and
UPLIFT trials.
These findings are largely in keeping with previous
observational studies, which have shown for the most
part enhanced survival with the use of ICS/LABA combi-
nations and a lack of survival benefits of short or long act-
ing bronchodilators by themselves [16-18]. However, our
findings appear discordant with a recent meta-analysis
published by Rodrigo and colleagues [19], which failed to
find a significant difference in total mortality between
those treated with ICS/LABA and those treated with
LABA only (though the point estimate was 0.90 in favor
of ICS/LABA). However , this study excluded trials that
did not have a LABA arm and failed to capture more
recently published clinical trials (e.g. studies by Tashkin
et al[20] and Rennard et al[21]). By adding these addi-
tional studies, the present meta-analysis had greater sta-
tistical power to determine the relationship of ICS/LABA
combination to total mortality. More importantly, in the
present meta-analysis, we compared the active treatment
groups (i.e. ICS/LABA or LABA or tiotropium) against
the primary reference group of the trial in order to pre-
serve the integrity of the original trial design and avoid
Figure 3 The Effects of Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Combination on Total Mortality Excluding Calverley et al's Trial 
[13]. Abbreviations: BUD/F, budesonide/formoterol combination; CI, confidence interval; ICS/LABA, inhaled corticosteroids/long-acting beta-2 agonist 
combination; M-H, Mantel-Hanzel; SALM, salmeterol; SFC, salmeterol/fluticasone combination
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the problem of multiple comparisons and post hoc analy-
ses. Thus, for the trials that used a 2 × 2 factorial design,
we compared the mortality effects of the active treatment
arm against the main reference group of the trial (which
in most cases was placebo) as the original trials did not
have sufficient power to assess interactions between the
groups or to correct for multiple comparisons [22].
The mechanism by which ICS/LABA combination
reduces total mortality in COPD is uncertain. It is now
well recognized that COPD is an inflammatory disorder,
characterized by persistent lung and systemic inflamma-
tion, which intensifies with disease progression and dur-
ing clinical exacerbations [23,24]. Once COPD develops,
the inflammatory response continues to persist many
years after smoking cessation [25]. Although the inflam-
matory process in COPD may be relatively insensitive to
the actions of glucocorticoids, the addition of a long-act-
ing beta-2 agonist to an inhaled corticosteroid appears to
amplify their anti-inflammatory effects both in vitro [26]
and in vivo [27,28]. For instance, Bourbeau and colleagues
found that 3 months of therapy with salmeterol/flutica-
sone combination attenuated lung inflammation, as char-
acterized by a reduction in the number of CD8 positive
and CD68 positive cells in the airways of patients with
severe, stable COPD; whereas fluticasone by itself had no
effect [28]. Similarly, Barnes and colleagues observed a
significant reduction in the expression of inflammatory
biomarkers in the bronchial biopsies and sputum of
COPD patients treated with salmeterol/fluticasone com-
bination compared to those treated with placebo [27].
These data have been replicated and extended by Lap-
perre and colleagues, who showed that salmeterol/fluti-
casone therapy for 30 months reduced lung
inflammation, attenuated the rate of decline in lung func-
tion, and improved bronchial responsiveness compared
to salmeterol alone or placebo[29]. Inhaled corticoster-
oid/long acting beta-2 agonist combination may also
attenuate the systemic inflammatory response in COPD
Figure 4 The Effects of Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Combination on Total Mortality Using Clinical Trials That Used 
Placebo-Treated Patients As The Main Comparator. Abbreviations: BUD/F, budesonide/formoterol combination; CI, confidence interval; ICS/LABA, 
inhaled corticosteroids/long-acting beta-2 agonist combination; M-H, Mantel-Hanzel; SALM, salmeterol; SFC, salmeterol/fluticasone combination
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Figure 5 The Effects of Long-Acting Beta-2 Agonists on Total Mortality. Abbreviations: CI, confidence interval; FORM, formoterol; LABA; long-act-
ing beta-2 agonists; M-H, Mantel-Hanzel; SALM, salmeterol
Study
SALM vs Placebo
Test for heterogeneity: P = 0.56
FORM vs Placebo
Test for heterogeneity: P = 0.31
Deaths Total Deaths Total Weight M-H, Random, 95% CI
LABA Placebo Risk Ratio Risk Ratio
M-H, Random, 95% CI
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Subtotal (95% CI) 24 1235 19 1242 6.6% 1.23 [0.61, 2.46]
Total (95% CI) 246 4030 273 4047 100.0% 0.90 [0.77, 1.06]
0.05 0.2 1 5 20
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Stockley 2006 [54]  6 316 5 318 1.9% 1.21 [0.37, 3.92]
Calverley 2003 [49] 5 372 10 361 2.3% 0.49 [0.17, 1.41]
Tashkin 2008 [20] 1 284 1 300 0.3% 1.06 [0.07, 16.81]
Rennard 2009 [21] 4 495 4 481 1.3% 0.97 [0.24, 3.86]
Calverley 2003 [49] 13 255 5 256 2.5% 2.61 [0.94, 7.21]
Mahler 2002 [52] 0 160 3 181 0.3% 0.16 [0.01, 3.10]
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Heterogeneity: Tau² = 0.00; Chi² = 7.59, df = 8 (P = 0.47); I² = 0%
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Figure 6 The Effects of Tiotropium on Total Mortality. Abbreviations: CI, confidence interval; ICS/LABA, inhaled corticosteroids/long-acting beta-
2 agonist combination; M-H, Mantel-Hanzel
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[30], which is associated with morbidity and mortality
[31,32].
In addition to their anti-inflammatory effects, combi-
nation therapy results in greater bronchodilation than
that achieved by the individual mono-components [13].
However, the combined bronchodilatory effects of
inhaled corticosteroid/beta-2 agonists is no better than
that achieved with tiotropium alone in COPD [15].
Despite this, the combination therapy results in superior
health status, and reduced mortality compared with
tiotropium alone [15], suggesting that mechanisms other
than bronchodilation and lung deflation are involved in
the mortality benefits of combination therapy.
There were limitations to the present study. We did not
have access to individualized data; thus, we could not
adjust for potential confounders. However, to mitigate
confounding, we chose large randomized controlled tri-
als, which were of high quality (Jadad Score of 3 or
greater) and had a reasonable duration of follow-up (6
months or greater), detailed accounting of all randomized
patients in the study and reported excellence balance in
terms of patient characteristics and clinical status
between the active treatment and comparator arms. Sec-
ondly, there was some heterogeneity in the doses and
drugs that were evaluated across the trials. We addressed
this issue by grouping the studies together, stratified
according to the drug formulation and dose and used a
conservative method of pooling the data (i.e. a random
effects model). Thirdly, we assessed total but not disease
specific mortality. We did not evaluate disease specific
mortality because assigning causality to deaths in COPD
is problematic [11]. Moreover, certain drugs have been
associated with increased risk of non-COPD related
health events such as pneumonia [33] and stroke [34],
which could have been missed by focusing on COPD-spe-
cific mortality alone. Fourthly, we did not evaluate the
effects of inhaled corticosteroids on total mortality
because recent studies have established that these drugs
do not impact on overall mortality and expert guidelines
in general do not recommend inhaled corticosteroids as
standalone therapies for COPD [13,33]. Fifthly, some
recent trials were performed on the background of bron-
chodilators, inhaled corticosteroids or both, which may
have diluted the possible mortality benefits of the drug in
question. This may be of particular concern in the most
recent tiotropium trial in which a majority of study
patients were taking ICS, LABA or both at the time of
recruitment [35]. Additionally, none of the studies
included in this meta-analysis except for Calverley et al.' s
study [13] was powered on mortality. As such, patients
with complex or life-threatening co-morbidities were
generally excluded from these trials, which likely reduced
the statistical power of the present study and limited the
generalizability of the findings to patients with multiple
co-morbidities. Another important consideration was the
differential drop-out rate between the active treatment
and the comparator arms of the study. Collectively, the
patients in the comparator arm were more likely to drop-
out of the trials compared with those who were assigned
to active treatment arm (38% versus 30%; p < .0001).
Although the precise effects of differential drop-out rate
are not fully known, it may have biased the results in
favor of the comparator arm, as patients who drop out are
generally sicker, less motivated and have poorer progno-
sis than those who remain in the study [36].
COPD is a worldwide epidemic affecting ~10% of
adults 40 years of age and older and accounting for more
than 3 million deaths annually. In China alone, there will
be nearly 1.5 million deaths this year from COPD [37].
Discouragingly, over the next 20 years, the worldwide
Figure 7 The Effects of Tiotropium on Total Mortality Using Clinical Trials That Used Placebo or Ipratropium Bromide As The Main Compar-
ator. Abbreviations: CI, confidence interval; ICS/LABA, inhaled corticosteroids/long-acting beta-2 agonist combination; M-H, Mantel-Hanzel
Study Deaths Total Deaths Total Weight M-H, Random, 95% CI
Tiotropium Placebo or Ipratropium Risk Ratio Risk Ratio
M-H, Random, 95% CI
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Brusasco 2003 [43] 1 402 5 400 0.3% 0.20 [0.02, 1.70]
Tonnel 2008 [42] 3 266 6 288 0.8% 0.54 [0.14, 2.14]
Vincken 2002 [14] 9 356 3 179 0.9% 1.51 [0.41, 5.50]
Chan 2007 [40] 17 608 4 305 1.3% 2.13 [0.72, 6.28]
Tashkin 2008 [35] 381 2987 411 3006 90.9% 0.93 [0.82, 1.06]
Total (95% CI) 440 6804 456 6183 100.0% 0.94 [0.83, 1.06]
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mortality from COPD will double [38]. The totality of
data from many large, randomized clinical trials indicates
that the combination of inhaled corticosteroids and long-
acting beta-2 agonists prolongs survival in COPD but
long-acting beta-2 agonists and tiotropium by themselves
do not. The survival effect, however, is fairly modest and
suggests a pressing need for additional pharmacothera-
pies that can reduce the overall mortality in COPD, which
in less than 10 years will be the 3rd leading cause of death
worldwide.
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